%0 Journal Article %J The Journal of allergy and clinical immunology %D 2007 %T Cost-effectiveness of omalizumab in adults with severe asthma: results from the Asthma Policy Model. %A Wu, Ann C %A Paltiel, A David %A Kuntz, Karen M %A Weiss, Scott T %A Fuhlbrigge, Anne L %K Anti-Allergic Agents %K Antibodies, Anti-Idiotypic %K Antibodies, Monoclonal %K Antibodies, Monoclonal, Humanized %K Asthma %K Cost-Benefit Analysis %K Humans %K Models, Theoretical %K Severity of Illness Index %N 5 %P 1146-52 %R 10.1111/j.1524-4733.2010.00763.x %V 120 %X Omalizumab (trade name Xolair) is approved by the US Food and Drug Administration for treatment of moderate-to-severe allergic asthma. Given the high acquisition cost of omalizumab, its role and cost-effectiveness in disease management require definition. %8 2007 Nov